Yes, I've noticed that. The boosters here are absolutely blind to the obvious problems with NNVC. Such as the fact that they never seem to make any real progress towards getting a salable, approved drug out the door. I know, toxicity testing and clinical trials are just so old fashioned, they don't apply to a magical company like NNVC, whose stock price will no doubt go to $100 a share solely on press releases about more preclinical trials of viricides on mice.
Market Data 
Markets 
AI
